National Institute on Drug Abuse; Notice of Meeting, 22093 [2016-08523]
Download as PDF
<![CDATA[
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 81, No. 72 / Thursday, April 14, 2016 / Notices
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.fda.gov/
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
Submit written requests for single
copies of the draft Environmental
Assessment (EA) and preliminary
Finding of No Significant Impact
(FONSI) to the Policy and Regulations
Staff (HFV–6), Center for Veterinary
Medicine, Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855. Send one selfaddressed adhesive label to assist that
office in processing your requests.
Persons with access to the Internet may
obtain the draft EA and preliminary
FONSI at either https://www.fda.gov/
animalveterinary/developmentapproval
process/environmentalassessments/
ucm300656.htm or https://
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Brinda Dass, Center for Veterinary
Medicine (HFV–2), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 240–276–8247,
email: abig@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In the
Federal Register of March 16, 2016,
FDA published a notice with a 30-day
comment period to request comments
on the Draft Environmental Assessment
and Preliminary Finding of No
Significant Impact Concerning
Investigational Use of Oxitec OX513A
Mosquitoes.
The Agency has received requests for
a 90-day extension of the comment
VerDate Sep<11>2014
17:56 Apr 13, 2016
Jkt 238001
period for the notice. Each request
conveyed concern that the current 30day comment period does not allow
sufficient time to develop a meaningful
or thoughtful response to the notice.
FDA has considered the requests and
is extending the comment period for the
notice for 30 days, until May 13, 2016.
The Agency believes that a 30-day
extension allows adequate time for
interested persons to submit comments
without significantly delaying the
Agency’s decision on whether to
finalize these documents or prepare an
Environmental Impact Statement.
Dated: April 7, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–08678 Filed 4–13–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Council on Drug
Abuse.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council on Drug Abuse.
Date: May 3–4, 2016.
Closed: May 3, 2016.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
22093
Open: May 4, 2016.
Time: 8:30 a.m. to 4:00 p.m.
Agenda: This portion of the meeting will
be open to the public for announcements and
reports of administrative, legislative, and
program developments in the drug abuse
field.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Contact Person: Susan R.B. Weiss, Ph.D.,
Director, Division of Extramural Research,
Office of the Director, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, NSC, Room 5274, MSC 9591,
Rockville, MD 20892, 301–443–6487,
sweiss@nida.nih.gov.
Any member of the public interested in
presenting oral comments to the committee
may notify the Contact Person listed on this
notice at least 10 days in advance of the
meeting. Interested individuals and
representatives of organizations may submit
a letter of intent, a brief description of the
organization represented, and a short
description of the oral presentation. Only one
representative of an organization may be
allowed to present oral comments and if
accepted by the committee, presentations
may be limited to five minutes. Both printed
and electronic copies are requested for the
record. In addition, any interested person
may file written comments with the
committee by forwarding their statement to
the Contact Person listed on this notice. The
statement should include the name, address,
telephone number and when applicable, the
business or professional affiliation of the
interested person.
Information is also available on the
Institute’s/Center’s home page:
www.drugabuse.gov/NACDA/
NACDAHome.html, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: April 8, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–08523 Filed 4–13–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Transportation Security Administration
Intent To Request Renewal From OMB
of One Current Public Collection of
Information: Baseline Assessment for
Security Enhancement (BASE)
Program
Transportation Security
Administration, DHS.
ACTION: 60-Day notice.
AGENCY:
The Transportation Security
Administration (TSA) invites public
SUMMARY:
E:\FR\FM\14APN1.SGM
14APN1
]]>Agencies
[Federal Register Volume 81, Number 72 (Thursday, April 14, 2016)]
[Notices]
[Page 22093]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-08523]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
National Advisory Council on Drug Abuse.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Council on Drug Abuse.
Date: May 3-4, 2016.
Closed: May 3, 2016.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications and/or
proposals.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852.
Open: May 4, 2016.
Time: 8:30 a.m. to 4:00 p.m.
Agenda: This portion of the meeting will be open to the public
for announcements and reports of administrative, legislative, and
program developments in the drug abuse field.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852.
Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of
Extramural Research, Office of the Director, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, NSC, Room 5274, MSC
9591, Rockville, MD 20892, 301-443-6487, sweiss@nida.nih.gov.
Any member of the public interested in presenting oral comments
to the committee may notify the Contact Person listed on this notice
at least 10 days in advance of the meeting. Interested individuals
and representatives of organizations may submit a letter of intent,
a brief description of the organization represented, and a short
description of the oral presentation. Only one representative of an
organization may be allowed to present oral comments and if accepted
by the committee, presentations may be limited to five minutes. Both
printed and electronic copies are requested for the record. In
addition, any interested person may file written comments with the
committee by forwarding their statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: www.drugabuse.gov/NACDA/NACDAHome.html, where an agenda and
any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: April 8, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-08523 Filed 4-13-16; 8:45 am]
BILLING CODE 4140-01-P
